EP Global Communications, Inc
(EPGL), (the Company),
(Pink Sheets: EPGL)
), the parent company of
) magazine, is pleased to announce that the new EP Health Sciences Division of the company is operational. The EP Health Sciences Division is utilizing the substantial network of resources that EPGL has established in both the fields of medicine and science over 40 years of existence.
“We are working with Dr. Norman Marcus and his innovative therapy coupled with the Muscle Pain Detection Device which has had significant beneficial results for many patients dealing with significant back pain. This intervention therapy addresses a market which has been estimated to be $85 billion in size and Dr. Marcus’ approach can help potentially millions of people experience relief from chronic pain for the first time," said Joe Valenzano, the CEO of EPGL. This marks a significant expanded direction for EPGL. Valenzano went on further to say that, “Dr. Marcus treated my condition, diagnosed as compressed or bulging discs in C-2 through C-7, with his intervention therapy and the MPDD and I am completely pain free today - after living with constant pain for over thirteen years.”
Dr. Marcus will be speaking on pain and pain management at the upcoming World Congress on Disabilities (
) in Dallas, Texas, November 18-19, 2010.
"Our goal is to help increase awareness of the MPDD and Dr. Marcus’ Therapy to the institutions that need it the most urgently due to the vast numbers of potential patients afflicted with pain,” Valenzano explained. “Our goal is to have this embraced by the medical community over the next several years via expanded knowledge, awareness and education.”
EPGL is also continuing work on developing a Resource Guide for the Nutraceutical Community, working collaboratively with Stephan DeFelice, MD. “We hope to have this product available in early 2011,” said Valenzano. The product itself will increase education and awareness and highlight the many issues faced by those utilizing Nutraceuticals in combination with Rx Medications and when such use may not be in the patient’s best interests.